CD274 and non-small cell lung carcinoma: In patients with stage IB-IIIA NSCLC treated with atezolizumab after surgery and adjuvant chemotherapy, disease-free survival (DFS) improved in the set of patients with PD-L1 ≥ 1%, while the set with PD-L1 ≥ 50% benefited the most [39].